Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320696 · ClinicalTrials.gov registry record · Phase 1
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Phase 1 study of Influenza, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 353
- Enrollment target
- 5
- Study locations
NCT01320696: Completed Phase 1 study of Influenza, sponsored by Alachua Government Services.
NCT01320696 is a Phase 1 study of Influenza that has completed, run by Alachua Government Services. The registered enrollment target is 353 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01320696, a Phase 1 study of Influenza, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 353 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
Conditions Studied
Interventions
- BIOLOGICAL Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Study Locations (5)
Alabama
- Accelovance - Huntsville
Florida
- Accelovance - Melbourne
Illinois
- Accelovance - Peoria
Indiana
- Accelovance - South Bend
Maryland
- Accelovance - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT01320696 record still lists
NCT01320696 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine is the first listed.
NCT01320696 lists 5 locations in 5 states (Alabama, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT01320696 about?
NCT01320696 is a clinical study titled "Reverse Genetic H9N2 Influenza Vaccine Study in Adults". The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
What is the current status of trial NCT01320696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 353 participants. The study started on 2011-03. Estimated completion is 2012-05.
What conditions does trial NCT01320696 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01320696?
The interventions under investigation include: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01320696?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01320696 being conducted?
This trial has 5 study locations across Alabama, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01320696's enrollment target sits among peer trials
353 56th of 156 higher than 101 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia